Analysts fell to the sidelines weighing in on Halozyme (HALO – Research Report) and SAGE Therapeutics (SAGE – Research Report) with neutral ...

Halozyme Therapeutics (NASDAQ:HALO – Free Report) had its price objective raised by Piper Sandler from $52.00 to $53.00 in a report published on Friday,Benzinga reports. They currently have a neutral ...

Wells Fargo lowered the firm’s price target on Halozyme (HALO) to $57 from $62 and keeps an Equal Weight rating on the shares. The firm said on ...

Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Zacks Research increased their Q1 2025 EPS estimates for shares of Halozyme Therapeutics in a report released on Tuesday, ...

Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on moves in the options market lately. That is because the March 21, 2025 $25.00 Call had some of the ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

Halozyme's attempt to acquire Evotec was a bold move to diversify revenue, but was ultimately unsuccessful, impacting HALO's ...

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...